India Q2 FY27 Earnings Roundup: Sun Pharma, Praj, Aether, Finolex Report Strong Results

The Quick Take

• Sun Pharmaceuticals reported 11.8% revenue growth to Rs 161,000 million in Q2 FY27
• Praj Industries posted higher Q2 FY27 profit on improved product mix and new contracts
• Aether Industries advances high-complexity CRAMS and signs a blockbuster agrochemical contract
• Finolex Industries reported 28% volume surge in pipes and fittings in Q2 FY27

India's Q2 FY27 earnings season delivered a strong batch of results across pharmaceuticals, specialty chemicals, and industrial materials, with Sun Pharmaceuticals leading the large-cap disclosure with 11.8% revenue growth to approximately Rs 161,000 million and an 80.8% gross margin that reflects the company's focus on complex generics and specialty branded products. Praj Industries reported profit growth on an improved product mix — the bioethanol-to-bioenergy diversification strategy is generating revenue from India's energy transition mandates — while Aether Industries, a specialty chemical manufacturer, signed a significant new CRAMS contract in the agrochemical sector.

The breadth of this earnings cluster, spanning 13 companies from pharma to chemicals to pipes, is a snapshot of India's manufacturing and specialty chemicals upcycle. Finolex Industries' 28% volume surge in pipes confirms the sustained residential and agricultural infrastructure demand that has underpinned the entire pipes sector for two years. The common thread across the cluster is operating leverage: companies that invested in capacity two to three years ago are now harvesting revenue on that capacity with relatively limited incremental fixed-cost increases, driving disproportionate profit growth versus revenue growth. This leverage effect is visible across Sun Pharma's gross margin, Aether's CRAMS contract economics, and Finolex's volume growth.

Investors with broad India equity exposure should use this earnings cluster as a cross-sector validation point. The key macro variable is India's overall GDP growth and domestic consumption — a broad-based deceleration would affect demand for pipes, specialty chemicals, and domestic pharmaceuticals simultaneously. Specific company watch-points include Sun Pharma's specialty product pipeline approvals from the USFDA, Aether's new CRAMS contract ramp-up timeline, and Praj Industries' next bioenergy project award from IOCL or HPCL. The cluster's strong margins suggest India's mid-cap manufacturing sector is in a sweet spot of the earnings cycle.

Synthesized from 13 sources.